Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics (NASDAQ:SRPT) will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025. A conference call to discuss results and recent corporate developments will follow at 4:30 p.m. ET.

The event will be webcast live via the investor relations site at https://investorrelations.sarepta.com/events-presentations and a replay will be archived there for one year. Phone participants must register online to receive dial-in details and a personal PIN by auto-generated email.

Sarepta Therapeutics (NASDAQ:SRPT) will present new clinical and real-world data at the 30th World Muscle Society Congress, Oct 7–11, 2025 in Vienna.

Presentations cover delandistrogene moxeparvovec (micro-dystrophin expression, safety, cardiac outcomes, mitigation of acute liver injury), a real-world pulmonary function study of casimersen, and EMERGENE phase 3 results for bidridistrogene xeboparvovec (SRP-9003) showing SGCB expression and safety in LGMD2E/R4. Multiple investigator-led delandistrogene abstracts (including sirolimus prophylaxis) will also be presented. Abstracts will be posted on Sarepta.com after the WMS embargo.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced equity inducement grants to 8 new employees hired in Q3 2025. The grants, approved under the company's 2024 Employment Commencement Incentive Plan, consist of 49,805 restricted stock units (RSUs). These RSUs will vest over four years, with 25% vesting annually on the grant date anniversary, contingent on continued employment.

The equity awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the Compensation Committee of Sarepta's Board of Directors.

Sarepta Therapeutics (NASDAQ:SRPT) has announced 25 recipients for its Route 79 Duchenne Scholarship Program for the 2025-2026 academic year. The program, now in its 8th year, will award $5,000 scholarships to 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals with the condition.

The scholarship recipients were selected by an independent committee based on academic records, community involvement, personal essays, and recommendation letters. Since its inception, the program has awarded more than 150 scholarships. The program's name, Route 79, references the 79 exons of the dystrophin gene, which is linked to Duchenne muscular dystrophy.

Sarepta Therapeutics (NASDAQ:SRPT) has announced a significant refinancing of its convertible notes through privately negotiated exchange agreements. The company will exchange approximately $700 million of its 1.25% convertible senior notes due 2027 for new 4.875% convertible notes due 2030 worth $602 million, along with up to 6.7 million shares of common stock and $123.3 million in cash.

The new convertible notes have an initial conversion rate of 16.6667 shares per $1,000 principal amount, equivalent to a conversion price of approximately $60.00 per share, representing a 191.5% premium. Additionally, Sarepta entered into a private placement agreement with J. Wood Capital Advisors LLC for up to 1.4 million shares of common stock. The transactions are expected to close around August 28, 2025.

Sarepta Therapeutics (NASDAQ:SRPT) announced two significant financial transactions related to its siRNA collaboration with Arrowhead Pharmaceuticals. The company has sold 9,265,312 shares of Arrowhead stock in a block trade for $174 million in gross proceeds. Additionally, Sarepta will transfer 2,660,989 shares to Arrowhead to satisfy $50 million of a $100 million milestone payment.

The milestone payment was triggered by positive safety data review and achievement of enrollment targets in the Phase 1/2 study of SRP-1003, an RNAi therapeutic for type 1 myotonic dystrophy (DM1). Preliminary data from this study is expected in second half of 2025.

Sarepta Therapeutics (NASDAQ:SRPT) reported strong Q2 2025 financial results with total revenues of $611.1 million, up 68% year-over-year. The company achieved GAAP net income of $196.9 million and resumed ELEVIDYS shipments for ambulatory Duchenne patients following FDA review.

Key highlights include net product revenues of $513.1 million, a 42% increase year-over-year, and progress on their restructuring plan targeting over $100 million in cost savings through 2025. The company is advancing multiple siRNA programs with clinical readouts expected in 2025-2026 for FSHD, DM1, SCA2, and Huntington's Disease.

The strategic restructuring announced in July 2025 aims to reduce expenses by $400 million annually starting in 2026, positioning the company to repay its 2027 convertible notes while maintaining focus on high-impact programs.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced it will release its second quarter 2025 financial results on Wednesday, August 6, 2025, after the Nasdaq market close. The company has noted that it will not host a conference call to discuss the results, as previously announced on July 16, 2025.

Sarepta maintains leadership positions in Duchenne muscular dystrophy treatments and is expanding its portfolio across muscle, central nervous system, and cardiac diseases.